● Recruiting

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Condition: Kidney Diseases · Kidney Diseases, Chronic · Urological Diseases · Sponsor: Novartis Pharmaceuticals

PhasePhase 3

Planned participants220

Who can joinAll sexes, 18 Years to 100 Years

Healthy volunteersNo

About this study

The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com

Novartis Pharmaceuticals · +41613241111

Always discuss trial participation with your own doctor first.

Locations (21)

Colorado Kidney Care Nephrology	Denver, Colorado, United States	Recruiting
Nephrology Associates Of Central FL	Orlando, Florida, United States	Recruiting
NY Nephrology	Clifton Park, New York, United States	Recruiting
Icahn School of Medicine at Mount Sinai	New York, New York, United States	Recruiting
Knoxville Kidney Center Pllc	Brentwood, Tennessee, United States	Recruiting
Dallas Renal Group	Dallas, Texas, United States	Recruiting
Dallas Renal Group	Dallas, Texas, United States	Recruiting
Nephro Asso North Illinois Indiana	Houston, Texas, United States	Recruiting
Novartis Investigative Site	Caba, Buenos Aires, Argentina	Recruiting
Novartis Investigative Site	La Plata, Buenos Aires, Argentina	Recruiting
Novartis Investigative Site	Buenos Aires, Buenos Aires F.D., Argentina	Recruiting
Novartis Investigative Site	Catamarca, Catamarca Province, Argentina	Recruiting

+ 9 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06858319